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The World Health Organization 
excludes Mycobacterium tuberculosis 
from the 2017 priority pathogens list 
To the Editor: On 27 February 2017 the World Health Organization 
(WHO) published the first priority pathogens list (PPL) for research 
and development of new antibiotics, which according to the WHO 
identifies ‘the most important resistant bacteria at a global level 
for which there is an urgent need for new treatments’. Selection 
criteria for prioritisation included: all-cause mortality, healthcare 
and community burden, prevalence of resistance, 10-year trend of 
resistance, transmissibility, preventability in hospital and community 
settings, and treatability and current pipeline, thereby making the 
exclusion of Mycobacterium tuberculosis from the PPL inconceivable, 
justifiably provoking the international medical and scientific frater-
nity. Drug-resistant tuberculosis (DR-TB) is a major global epidemic, 
with 0.5 million cases occurring each year.[1] Extensively DR-TB 
(XDR-TB), in particular, is of major concern, with poor treatment 
success rates of <40% in most patient populations, and mortality rates 
of 50 - 80%.[2-6] 
The exclusion of M. tuberculosis from the PPL creates the 
impression that DR-TB is not a public health threat, undoubtedly 
preventing prioritisiation of TB research by policy-makers. This is not 
negotiable. It is noteworthy that the WHO finally dedicated resources 
to identify a PPL. However, central to the integrity of the report is 
surely the inclusion of M. tuberculosis as a key priority pathogen. 
The drug development pipeline for anti-TB drugs is narrow. Existing 
drugs are associated with serious adverse effects, such as irreversible 
ototoxicity, nephrotoxicity, debilitating nausea and psychosis. After 
five decades, two new anti-TB drugs, bedaquiline and delamanid, 
were developed, with an accelerated approval of bedaquiline.
DR-TB remains an ongoing global health threat, with high levels 
of mortality and persistent limited treatment options. Other new 
options include pretomanid, and older repurposed drugs such 
as clofazimine. The combination of bedaquiline, pretomanid and 
linezolid was recently shown to be very effective in the NIX-TB 
clinical trial, reinforcing the positive impact of research. Seventy-two 
patients were recruited from April 2015; 65% of these patients had 
XDR-TB, while the remaining patients had multidrug-resistant TB 
(MDR-TB) and were either not responding to treatment or could 
not tolerate the side-effects. Just over half were HIV-positive. Forty 
patients have completed the 6-month trial and 31 have had their 
6-monthly follow-up examination. Of these 31 patients, only one 
relapsed.[7] 
The release of the WHO PPL coincides with the report ‘Mortality 
and causes of death in South Africa, 2015: Findings from death 
notification’, which highlights that ‘tuberculosis was the leading 
cause of death in both males and females in 2015, in South Africa’.[8] 
Exclusion of TB in the WHO PPL negates acceleration of research 
and development efforts in DR-TB treatment. This is a violation of 
fundamental human rights, and will likely impede access to effective 
drugs for this deadly disease.
By adopting the decision to exclude TB in the PPL, the WHO runs 
the risk of being viewed as purveyors of ill-informed science. We 
therefore urgently call on the WHO to facilitate a timely review of the 
impact of M. tuberculosis resistance globally, which certainly warrants 
its inclusion in the global PPL.
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